
Protalix BioTherapeutics PLX
$ 2.42
-0.41%
Quarterly report 2024-Q3
added 11-14-2024
Country |
![]() |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSE AMERICAN |
CEO |
Mr. Dror Bashan |
Employees in the company |
196 |
Shares |
67.5 M |
Market Cap[1] |
$ 163 M |
EBITDA (LTM) |
$ -11.1 M |
P/E (LTM) |
5.22 |
P/S (LTM) |
1.24 |
EPS (LTM) |
0.27 |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.